However, the results of the CheckMate 227 clinical trial indicated that PD-L1-negative NSCLC patients could still show a benefit from ICB treatment; additionally, a subset of patients with PD-L1-negative expression exhibited significantly prolonged survival (Hellmann et al., 2019). The gene discussed is CD274; the disease is non-small cell lung carcinoma.